Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 3/20 | 0.43 |
| ▸ | IGF1R | P08069 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | ITK | Q08881 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16101870 | 1.00 | CDK1 (0.49) | CDK1CDK2CCNB1CCNE1BTK | |
| SCHEMBL4712780 | 0.87 | CDK1 (0.53) | CDK1CDK2CCNB1CCNE1BTK | |
| SCHEMBL4712777 | 0.87 | CDK1 (0.53) | CDK1CDK2CCNB1CCNE1BTK | |
| SCHEMBL16100026 | 0.77 | ALDH1A1 (0.35) | SMN1; SMN2MEN1GAAMAPTRAB9A | |
| SCHEMBL16100027 | 0.77 | ALDH1A1 (0.35) | SMN1; SMN2MEN1GAAMAPTRAB9A | |
| SCHEMBL16120578 | 0.70 | SYK (0.46) | CDK1IGF1RKDRAURKASYK | |
| SCHEMBL3408870 | 0.69 | TDP1 (0.65) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16100631 | 0.69 | ALK (0.53) | CDK2JAK2SYKNTRK1LCK | |
| SCHEMBL16100630 | 0.69 | ALK (0.53) | CDK2JAK2SYKNTRK1LCK | |
| SCHEMBL4716152 | 0.68 | EGFR (0.53) | CDK1CDK2BTKITKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3733184-B1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3733184-A1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Icahn School of Medicine at Mount Sinai (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-2968331-B1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-01 | — | — | EP | disclosed |
| US-9815847-B2 | Pyrimidine compounds as kinase inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2016-05-05 | — | — | US | disclosed |
| EP-2968331-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | Icahn School of Medicine at Mount Sinai (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151682-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | DCK, TK1, DTYMK | CDK1 15/4885CDK2 6/4885CCNB1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.